Related Experiment Video

Updated: May 27, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection

Debora L S Danilovic1, Maria C Mendes-Correa, Erika U Lima

  • 1Unidade de Tireóide - Laboratório de Endocrinologia Celular e Molecular - LIM 25 Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. deboraseguro@hotmail.com

Liver International : Official Journal of the International Association for the Study of the Liver
|December 6, 2011
PubMed
Abstract

Insights

Cytotoxic T lymphocyte-associated factor 4 (CTLA-4) gene polymorphisms are linked to hepatitis C virus (HCV) infection. Specific CTLA-4 variants correlate with HCV genotypes and disease severity, including increased liver inflammation.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Molecular Biology

Background:

  • Cytotoxic T lymphocyte-associated factor 4 (CTLA-4) is a key negative regulator of T cell immune responses.
  • Polymorphisms in the CTLA-4 gene may impact its regulatory function and influence immune-mediated diseases like chronic hepatitis C.
  • Understanding these genetic variations is crucial for deciphering disease pathogenesis and progression.

Purpose of the Study:

  • To investigate the prevalence of CTLA-4 gene polymorphisms in patients with chronic hepatitis C virus (HCV) infection.
  • To correlate these genetic variations with clinical characteristics and histological liver findings in HCV-infected individuals.

Main Methods:

  • Prospective evaluation of 112 HCV-infected patients and 183 healthy controls.
  • Analysis of clinical and liver biopsy data.
  • Genotyping of CTLA-4 single-nucleotide polymorphisms (-318C>T, A49G, CT60) using PCR-RFLP and AT(n) polymorphism via DNA fragment analysis.

Main Results:

  • A higher frequency of eight AT repetitions in the 3'UTR region was observed in HCV-infected subjects.
  • The -318C and +49G alleles were associated with HCV genotype 3 and inversely with genotype 1.
  • +49G and CT60 G alleles correlated with elevated aminotransferase levels.
  • An increased number of AT repetitions was linked to severe necroinflammatory activity in liver biopsies.

Conclusions:

  • CTLA-4 gene polymorphisms are significantly associated with HCV infection.
  • The prevalence of specific CTLA-4 variants differs between HCV genotypes and influences disease activity.
  • The number of AT repetitions in the CTLA-4 3'UTR region is a potential biomarker for severe liver inflammation in HCV patients.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...